Download our whitepaper,

Optimizing Pulmonary Arterial
Hypertension Clinical Trials:
Diagnosis, Challenges, and
Breakthroughs

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Pulmonary Arterial Hypertension Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Pulmonary Arterial Hypertension.
  • Comprehensive Analysis of FDA-Approved Pulmonary Arterial Hypertension Drugs.
  • How Diagnostic Criteria for Pulmonary Arterial Hypertension Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Pulmonary Arterial Hypertension Clinical Trials.
  • And additional insights to drive your trial’s success.

Access your complimentary whitepaper today:






    Pulmonary Arterial Hypertension Clinical Trials

    Pulmonary Arterial Hypertension (PAH) is a rare but life-threatening condition characterized by elevated blood pressure in the pulmonary arteries, which connect the heart to the lungs.

    The increased pressure results from the narrowing and stiffening of these arteries, leading to restricted blood flow. As a result, the right side of the heart must work harder to pump blood through the lungs. Over time, this additional strain can cause right heart failure — a primary cause of death among patients with PAH. If left untreated, PAH can be fatal within a few years of diagnosis.

    iNGENū’s team of researchers and clinicians is dedicated to advancing Pulmonary Arterial Hypertension research. Through innovative trial designs and a patient-centered approach, we accelerate the development of new treatments that may improve outcomes and quality of life for those affected by this challenging condition.

    3x

    more likely for women to develop Pulmonary Arterial Hypertension

    40%

    of patients with untreated PAH develop right heart failure

    10%

    of PAH cases are heritable, often linked to mutations in the BMPR2 gene

    Our clinical team has over

    120 years

    of combined clinical trial experience